🇺🇸 FDA
Patent

US 6468983

RNase L activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies

expired A61KA61K38/00A61P

Quick answer

US patent 6468983 (RNase L activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Oct 17 2022 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Oct 22 2002 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 17 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
29
CPC classes
A61K, A61K38/00, A61P, A61P35/00, A61P43/00